DDInter1726 DDInter899
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Sulfinpyrazone {u} (Compound) resembles {v} (Compound) Diphenoxylate
Sulfinpyrazone {u} (Compound) binds {v} (Gene) CYP2C8
Sulfinpyrazone {u} (Compound) upregulates {v} (Gene) ST3GAL5
Sulfinpyrazone {u} (Compound) downregulates {v} (Gene) TXNDC9
Sulfinpyrazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Sulfinpyrazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Exemestane
Sulfinpyrazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivacaftor
Sulfinpyrazone {u} may lead to a major life threatening interaction when taken with {v} Acalabrutinib
Sulfinpyrazone {u} may lead to a major life threatening interaction when taken with {v} Ibritumomab tiuxetan
Sulfinpyrazone (Compound) resembles Diphenoxylate (Compound)
Sulfinpyrazone (Compound) binds CYP2C8 (Gene)
Sulfinpyrazone (Compound) upregulates ST3GAL5 (Gene)
Sulfinpyrazone (Compound) downregulates TXNDC9 (Gene)
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Exemestane
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor
Sulfinpyrazone may lead to a major life threatening interaction when taken with Acalabrutinib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan